ARS Pharmaceuticals, Inc. Cash Flow Statement
SPRY / Health Care|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
ARS Pharmaceuticals, Inc. used $171M in operating cash flow and negative free cash flow of $171M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$171.3M | $8.0M | -$54.4M | -$20.2M | -$20.2M | -$32.9M |
| Depreciation & Amortization | $1.4M | $79.0K | $100.0K | - | $783.0K | $637.0K |
| Operating Cash Flow | -$170.9M | $13.5M | -$59.3M | -$17.6M | -$17.6M | -$31.2M |
| Capital Expenditures | $339.0K | $563.0K | $175.0K | $55.0K | $55.0K | $917.0K |
| Free Cash Flow | -$171.2M | $13.0M | -$59.4M | -$17.6M | -$17.6M | -$32.1M |
| FCF Margin | -203.1% | 14.6% | -198136.7% | -319.9% | - | - |